London
· Delayed Price · Currency is GBP · Price in USD Corbus Pharmaceuticals Holdings Company Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness.
It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
The company was incorporated in 2009 and is based in Norwood, Massachusetts.
| Country | United States |
| Founded | 2009 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Yuval Cohen |
Contact Details
Address: 500 River Ridge Drive Norwood, Delaware 02062 United States | |
| Phone | 617 963 0100 |
| Website | corbuspharma.com |
Stock Details
| Ticker Symbol | 0SZI |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US21833P3010 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yuval Cohen | Chief Executive Officer |
| Sean Moran | Chief Financial Officer |